ZALCITABINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C9H13N3O3
Molecular Weight	211.2178
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=NC(=O)N(C=C1)[C@H]2CC[C@@H](CO)O2

InChI

InChIKey=WREGKURFCTUGRC-POYBYMJQSA-N

InChI=1S/C9H13N3O3/c10-7-3-4-12(9(14)11-7)8-2-1-6(5-13)15-8/h3-4,6,8,13H,1-2,5H2,(H2,10,11,14)/t6-,8+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C9H13N3O3
Molecular Weight	211.2178
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s16lbl.pdf

The nucleoside analog 2',3'-dideoxycytidine (ddCyd), also known as Zalcitabine is a nucleoside analog reverse transcriptase inhibitor (NRTI) sold under the trade name Hivid. HIVID is indicated in combination with antiretroviral agents for the treatment of HIV infection. It is used as part of a combination regimen with antiretroviral agents. But it was discontinued by Roche Pharmaceuticals on December 31, 2006 due to the availability of newer HIV medicines. Within cells, zalcitabine is converted to the active metabolite, dideoxycytidine 5'-triphosphate (ddCTP), by the sequential action of cellular enzymes. Dideoxycytidine 5'-triphosphate inhibits the activity of the HIV-reverse transcriptase both by competing for utilization of the natural substrate, deoxycytidine 5'-triphosphate (dCTP), and by its incorporation into viral DNA. The lack of a 3'- OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation and, therefore, the viral DNA growth is terminated. The active metabolite, ddCTP, is also an inhibitor of cellular DNA polymerasebeta and mitochondrial DNA polymerase-gamma and has been reported to be incorporated into the DNA of cells in culture.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Human immunodeficiency virus type 1 reverse transcriptase 67 Target ID: CHEMBL247 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9179531	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
HIV infection 21 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s16lbl.pdf	Primary		Approved 8429	HIVID Approved Use HIVID is indicated in combination with antiretroviral agents for the treatment of HIV infection. This indication is based on study results showing a reduction in the rate of disease progression (AIDS-defining events or death) in patients with limited prior antiretroviral therapy who were treated with the combination of HIVID and zidovudine. This indication is also based on a study showing a reduction in both mortality and AIDS-defining clinical events for patients who received INVIRASE® (saquinavir mesylate) in combination with HIVID compared to patients who received either HIVID or INVIRASE alone. Launch Date 7.0891202E11

C_max

Value	Dose	Analyte	Population
7.6 μg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9179531/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZALCITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
10.5 μg/L REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf	0.5 mg single, intravenous dose: 0.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZALCITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
79 μg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9179531/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZALCITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
9.3 μg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9179531/	0.02 mg/kg bw single, oral dose: 0.02 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	ZALCITABINE plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
15.5 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf	1.5 mg single, oral dose: 1.5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZALCITABINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: FED
25.2 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf	1.5 mg single, oral dose: 1.5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZALCITABINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: FASTED

AUC

Value	Dose	Analyte	Population
0.018 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9179531/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZALCITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.022 mg × h/L REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf	0.5 mg single, intravenous dose: 0.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZALCITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.208 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9179531/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZALCITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.025 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9179531/	0.02 mg/kg bw single, oral dose: 0.02 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	ZALCITABINE plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
62 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf	1.5 mg single, oral dose: 1.5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZALCITABINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: FED
72 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf	1.5 mg single, oral dose: 1.5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZALCITABINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: FASTED

T_1/2

Value	Dose	Analyte	Population
1.5 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9179531/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZALCITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.3 h REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf	0.5 mg single, intravenous dose: 0.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZALCITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.8 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9179531/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZALCITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.4 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9179531/	0.02 mg/kg bw single, oral dose: 0.02 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	ZALCITABINE plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
2 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf	1.5 mg single, oral dose: 1.5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZALCITABINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: FED
2 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf	1.5 mg single, oral dose: 1.5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZALCITABINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
96% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf	1.5 mg single, oral dose: 1.5 mg route of administration: Oral experiment type: SINGLE co-administered:		ZALCITABINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: FED
96% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf	1.5 mg single, oral dose: 1.5 mg route of administration: Oral experiment type: SINGLE co-administered:		ZALCITABINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: FASTED

Doses

Dose	Population	Adverse events
0.09 mg/kg 6 times / day multiple, oral Dose: 0.09 mg/kg, 6 times / day Route: oral Route: multiple Dose: 0.09 mg/kg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2558314 Page: p.858	unhealthy, 26-57 n = 5 Health Status: unhealthy Condition: HIV infection Age Group: 26-57 Sex: M Population Size: 5 Sources: https://pubmed.ncbi.nlm.nih.gov/2558314 Page: p.858	Disc. AE: Peripheral neuropathy, Leukopenia... AEs leading to discontinuation/dose reduction: Peripheral neuropathy (40%) Leukopenia (20%) Thrombocytopenia (40%) Sources: https://pubmed.ncbi.nlm.nih.gov/2558314 Page: p.858
0.06 mg/kg 6 times / day multiple, oral Highest studied dose Dose: 0.06 mg/kg, 6 times / day Route: oral Route: multiple Dose: 0.06 mg/kg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2536257 Page: p.191	unhealthy, 42 n = 18 Health Status: unhealthy Condition: HIV infection Age Group: 42 Sex: M+F Population Size: 18 Sources: https://pubmed.ncbi.nlm.nih.gov/2536257 Page: p.191	Disc. AE: Peripheral neuropathy... AEs leading to discontinuation/dose reduction: Peripheral neuropathy (grade 3, 100%) Sources: https://pubmed.ncbi.nlm.nih.gov/2536257 Page: p.191
0.03 mg/kg 6 times / day multiple, oral Dose: 0.03 mg/kg, 6 times / day Route: oral Route: multiple Dose: 0.03 mg/kg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2536257 Page: p.191	unhealthy, 42 n = 18 Health Status: unhealthy Condition: HIV infection Age Group: 42 Sex: M+F Population Size: 18 Sources: https://pubmed.ncbi.nlm.nih.gov/2536257 Page: p.191	Disc. AE: Peripheral neuropathy... AEs leading to discontinuation/dose reduction: Peripheral neuropathy (grade 3, 100%) Sources: https://pubmed.ncbi.nlm.nih.gov/2536257 Page: p.191
1.5 mg 3 times / day multiple, oral Overdose Dose: 1.5 mg, 3 times / day Route: oral Route: multiple Dose: 1.5 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf Page: p.18	unhealthy Health Status: unhealthy Condition: HIV infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf Page: p.18	Other AEs: Peripheral neuropathy... Other AEs: Peripheral neuropathy (80%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf Page: p.18
4.5 mg 3 times / day multiple, oral Overdose Dose: 4.5 mg, 3 times / day Route: oral Route: multiple Dose: 4.5 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf Page: p.18	unhealthy Health Status: unhealthy Condition: HIV infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf Page: p.18	Other AEs: Peripheral neuropathy... Other AEs: Peripheral neuropathy (100%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf Page: p.18
0.25 mg/kg 3 times / day multiple, oral Overdose Dose: 0.25 mg/kg, 3 times / day Route: oral Route: multiple Dose: 0.25 mg/kg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf Page: p.18	unhealthy Health Status: unhealthy Condition: HIV infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf Page: p.18	Disc. AE: Rash, Fever... AEs leading to discontinuation/dose reduction: Rash Fever Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf Page: p.18
0.75 mg 3 times / day multiple, oral Recommended Dose: 0.75 mg, 3 times / day Route: oral Route: multiple Dose: 0.75 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: HIV infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf Page: p.1	Other AEs: Peripheral neuropathy... Other AEs: Peripheral neuropathy (grade 3-5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf Page: p.1
0.75 mg 3 times / day multiple, oral Recommended Dose: 0.75 mg, 3 times / day Route: oral Route: multiple Dose: 0.75 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf Page: p.1, p.7	unhealthy Health Status: unhealthy Condition: HIV infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf Page: p.1, p.7	Other AEs: Lactic acidosis, Hepatic steatosis... Other AEs: Lactic acidosis (grade 3-5) Hepatic steatosis (grade 3-5) Hepatic failure (grade 3-5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf Page: p.1, p.7
0.75 mg 3 times / day multiple, oral Recommended Dose: 0.75 mg, 3 times / day Route: oral Route: multiple Dose: 0.75 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf Page: p.7	unhealthy Health Status: unhealthy Condition: HIV infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf Page: p.7	Other AEs: Pancreatitis, Oral ulceration... Other AEs: Pancreatitis (grade 3-5, 1.1%) Oral ulceration (grade 3, 3%) Esophageal ulcer (grade 3) Cardiomyopathy (grade 3, infrequent) Congestive heart failure (grade 3, infrequent) Anaphylactoid reaction (grade 3) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf Page: p.7

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	OAT1 326

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
OAT1 326	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16724555/	not determined

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:10101	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:10101
ChemicalBook	CB2369466	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2369466
MolPort	MolPort-002-885-873	https://www.molport.com/shop/molecule-link/MolPort-002-885-873
Selleck Chemicals	Zalcitabine	http://www.selleckchem.com/products/Zalcitabine.html
ZINC	ZINC000000039906	http://zinc15.docking.org/substances/ZINC000000039906
eMolecules	29549673	https://www.emolecules.com/cgi-bin/more?vid=29549673
eMolecules	501711	https://www.emolecules.com/cgi-bin/more?vid=501711

PubMed

Title	Date	PubMed
ddC- and 3TC-bis(SATE) monophosphate prodrugs overcome cellular resistance mechanisms to HIV-1 associated with cytidine kinase deficiency.	1999 Apr-May	10432710
Activities of masked 2',3'-dideoxynucleoside monophosphate derivatives against human immunodeficiency virus in resting macrophages.	2000 Jan	10602742
Potentiation of the anti-HIV activity of zalcitabine and lamivudine by a CTP synthase inhibitor, 3-deazauridine.	2000 Jan-Feb	10772721
Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine.	2000 May	10770740
Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography.	2001 Apr 13	11355843
Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.	2001 Aug 15	11471110
Simultaneous quantitation of nucleoside HIV-1 reverse transcriptase inhibitors by short-end injection capillary electrochromatography on a beta-cyclodextrin-bonded silica stationary phase.	2001 Aug 24	11572385
Synthesis and chain length-anti-HIV activity relationship of fully N- and O-sulfated homooligomers of tyrosine.	2001 Feb	11249140
MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine.	2001 Jan	11737372
Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians.	2001 Jan	11191730
Crystal structures of a ddATP-, ddTTP-, ddCTP, and ddGTP- trapped ternary complex of Klentaq1: insights into nucleotide incorporation and selectivity.	2001 Jun	11369861
Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).	2001 Jun 15	11372025
Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma.	2001 Jun 29	11319228
Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells.	2001 Sep	11504818
Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro.	2001 Sep	11448730
Novel direct detection method for quantitative determination of intracellular nucleoside triphosphates using weak anion exchange liquid chromatography/tandem mass spectrometry.	2002	11992513
New developments in anti-HIV chemotherapy.	2002 Jul 18	12084468
ViroLogic announces agreement with Achillion.	2002 Mar	11981960
Novel use of a guanosine prodrug approach to convert 2',3'-didehydro-2',3'-dideoxyguanosine into a viable antiviral agent.	2002 Mar	11850281
Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors.	2002 Mar	11850253
Certification of the critical importance of L-3-(2-naphthyl)alanine at position 3 of a specific CXCR4 inhibitor, T140, leads to an exploratory performance of its downsizing study.	2002 May	11886804
Impact of highly active antiretroviral therapy on cognitive processing in HIV infection: cross-sectional and longitudinal studies of event-related potentials.	2002 May 1	12015901

Patents

Sample Use Guides

In Vivo Use Guide

Patients should be advised that HIVID is recommended for use in combination with active antiretroviral therapy. Greater activity has been observed when new antiretroviral therapies are begun at the same time as HIVID. Concomitant therapy should be based on a patient’s prior drug exposure. The recommended regimen is one 0.750 mg tablet of HIVID orally every 8 hours (2.25 mg HIVID total daily dose) in combination with other antiretroviral agents. Please refer to the complete product information for each of the other antiretroviral agents for the recommended doses of these agents. Based on preliminary data, the recommended HIVID dosage reduction for patients with impaired renal function is: creatinine clearance 10 to 40 mL/min: 0.750 mg of HIVID every 12 hours; creatinine clearance <10 mL/min: 0.750 mg of HIVID every 24 hours.

Route of Administration: Oral

In Vitro Use Guide

2',3'-Dideoxycytidine (DDC) was evaluated for prophylactic antiviral activity in vitro using the feline leukemia virus (FeLV)-cat animal model. In vitro antiviral activity of DDC against FeLV was dependent upon the target cell used for infection. DDC (5 to 10 microM) inhibited FeLV infection of feline lymphoid cells by greater than 80%, while 6.07 to 12.13 uM DDC was required to similarly inhibit infection of feline fibroblasts. However, 43 to 384 uM DDC was needed to inhibit FeLV infection of primary bone marrow cells by greater than 80%. These in vitro results suggest that, although relatively low doses of DDC may be adequate to prevent infection of feline lymphoid cells, 8- to 80-times-higher doses may be necessary to block infection of bone marrow cells, a primary target cell type for FeLV infection. Results of in vitro studies suggest that feline bone marrow cells may remain partially susceptible to FeLV infection at tolerated doses, while other somatic target tissues (i.e., lymphoid or epithelial tissues) may be protected from infection.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 05:31:55 UTC 2023` Edited by `admin` on `Sat Dec 16 05:31:55 UTC 2023`
Record UNII	6L3XT8CB3I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZALCITABINE

Official Name

English

ZALCITABINE [USAN]

Common Name

English

ZALCITABINE [ORANGE BOOK]

Common Name

English

2',3'-DIDEOXYCYTIDINE

Systematic Name

English

RO 24-2027/000

Code

English

ZALCITABINE [HSDB]

Common Name

English

ZALCITABINE [JAN]

Common Name

English

ZALCITABINE (DIDEOXYCYTIDINE,DDC) [VANDF]

Common Name

English

RO-24-2027/000

Code

English

HIVID

Brand Name

English

Zalcitabine [WHO-DD]

Common Name

English

NSC-606170

Code

English

ZALCITABINE [IARC]

Common Name

English

ZALCITABINE [USP-RS]

Common Name

English

DIDEOXYCYTIDINE

Systematic Name

English

RO-242027000

Code

English

ZALCITABINE [MART.]

Common Name

English

ZALCITABINE [VANDF]

Common Name

English

DDC

Common Name

English

CYTIDINE, 2',3'-DIDEOXY-

Systematic Name

English

zalcitabine [INN]

Common Name

English

ZALCITABINE [MI]

Common Name

English

RO-24-2027000

Code

English

ZALCITABINE [USP IMPURITY]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QJ05AF03